Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGSWW) EBITDA Margin (2020 - 2025)

GeneDx Holdings has reported EBITDA Margin over the past 6 years, most recently at 14.66% for Q4 2025.

  • Quarterly results put EBITDA Margin at 14.66% for Q4 2025, down 2025.0% from a year ago — trailing twelve months through Dec 2025 was 4.89% (up 1209.0% YoY), and the annual figure for FY2025 was 4.89%, up 1209.0%.
  • EBITDA Margin for Q4 2025 was 14.66% at GeneDx Holdings, down from 6.38% in the prior quarter.
  • Over the last five years, EBITDA Margin for WGSWW hit a ceiling of 75.8% in Q3 2021 and a floor of 503.28% in Q4 2022.
  • Median EBITDA Margin over the past 5 years was 56.83% (2021), compared with a mean of 91.19%.
  • Biggest five-year swings in EBITDA Margin: crashed -43375bps in 2022 and later skyrocketed 45913bps in 2023.
  • GeneDx Holdings' EBITDA Margin stood at 69.52% in 2021, then crashed by -624bps to 503.28% in 2022, then surged by 91bps to 44.15% in 2023, then surged by 113bps to 5.59% in 2024, then tumbled by -362bps to 14.66% in 2025.
  • The last three reported values for EBITDA Margin were 14.66% (Q4 2025), 6.38% (Q3 2025), and 10.44% (Q2 2025) per Business Quant data.